MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Supernus Pharmaceuticals Company Profile (NASDAQ:SUPN)

Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.67 (25.55% upside)

Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Show:
DateFirmActionRatingPrice TargetActions
5/12/2016Jefferies GroupReiterated RatingBuy$19.00 -> $23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016Piper JaffrayReiterated RatingOverweight$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Northland SecuritiesReiterated RatingOutperform$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2015Stifel NicolausBoost Price TargetBuy$15.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/12/2015SunTrustInitiated CoverageBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/9/2015GuggenheimInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha